Retrospective observational study to investigate the predictive factors about the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.

Retrospective observational study to investigate the predictive factors about the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma. - Retrospective observational study to investigate the predictive factors about the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010001

Enrollment

400

Registered

2013-02-08

Start date

2012-06-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced hepatocellular carcinoma treated with sorafenib.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Secondary

Measure	Time frame
The clinicopathological factors related to overall survival of unresectable advanced hepatocellular carcinoma patients treated with sorafenib. The clinicopathological factors to predict serious adverse effects caused by sorafenib.	—

Primary

Measure	Time frame
The clinicopathological factors related to time to progression of unresectable advanced hepatocellular carcinoma.patients treated with sorafenib.	—

Countries

Japan

Contacts

Public ContactYukio Osaki

Osaka Red Cross Hospital Depertment of Gastroenterology and Hepatology

Outcome results